默克公司正在试图追赶统治新一代丙型肝炎药物市场的吉列德。吉列德的药物可以治愈90%以上的肝炎患者。
Merck is trying to catch up to Gilead, which dominates the market on a new generation of hepatitis C drugs that can cure well over 90 percent of patients with the liver disease.